Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
LAWRENCE, Mass., May 14, 2012 /PRNewswire/ — NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that former NxStage® System One(TM) patient Nikolas Gieske of Mequon, Wisconsin, received a kidney transplant following four successful years of more frequent home hemodialysis with the System One.
The freedom to do his dialysis treatments on his own schedule enabled Nikolas to live more independently while pursuing his college degree at the Milwaukee School of Engineering, where he is currently enrolled in his junior year and studying software engineering. In September of 2011, Nikolas, who was on a transplant list, learned there was a “perfect-match” kidney available for him, and underwent the transplant procedure shortly after.
“I only wanted to pursue a kidney transplant if it was a perfect match for me because I already had a high quality of life as a System One patient,” says Nikolas Gieske. “I believe my more frequent therapy schedule played a role in helping me to be healthy enough to receive my new kidney. The ability of the System One to take a complex medical treatment, and engineer it to be easy to use has inspired me to pursue a career in engineering. I hope to someday be able to design similar products to help people.”
In addition to his parents, Nikolas’ brother, Mitchell, helped Nikolas receive treatments with the System One as one of his trained partners. Through his experience as a dialysis care partner, Mitchell was inspired to pursue a career in medicine, and was recently accepted on a full academic scholarship to the Milwaukee School of Engineering School of Nursing. Mitchell will join his brother as a student in Fall 2013.
“NxStage is excited to celebrate Nikolas’ successful transplant,” says Jeffrey Burbank, Chief Executive Officer of NxStage Medical. “Given the growing clinical evidence in support of more frequent, daily home hemodialysis, it’s clear that our therapy allows many of our patients to live longer, better lives.”
To learn more about Nikolas’ story visit: http://www.nxstage.com/blog.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq:NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com/.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE NxStage Medical, Inc.